Dacarbazine (DTIC) versus vaccination with autologous peptide-pulsed dendritic cells (DC) in first-line treatment of patients with metastatic melanoma: a randomized phase III trial of the DC study group of the DeCOG

New Guidelines to Evaluate the Response to Treatment in Solid Tumors

2000 • 15,583 citations

Cancer immunotherapy: moving beyond current vaccines

2004 • 2,932 citations

Vaccination of melanoma patients with peptide- or tumorlysate-pulsed dendritic cells

1998 • 2,916 citations

Prognostic Factors Analysis of 17,600 Melanoma Patients: Validation of the American Joint Committee on Cancer Melanoma Staging System

2001 • 2,365 citations

Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma

1998 • 1,826 citations

Vaccination with Mage-3a1 Peptide–Pulsed Mature, Monocyte-Derived Dendritic Cells Expands Specific Cytotoxic T Cells and Induces Regression of Some Metastases in Advanced Stage IV Melanoma

1999 • 1,260 citations

Randomized Phase III Study of Temozolomide Versus Dacarbazine in the Treatment of Patients With Advanced Metastatic Malignant Melanoma

2000 • 1,252 citations

Subgroup analysis, covariate adjustment and baseline comparisons in clinical trial reporting: current practiceand problems

2002 • 1,023 citations

Induction of cytotoxic T-lymphocyte responses in vivo after vaccinations with peptide-pulsed dendritic cells

2000 • 544 citations

Generation of large numbers of fully mature and stable dendritic cells from leukapheresis products for clinical application

1999 • 499 citations

Rapid Induction of Tumor-specific Type 1 T Helper Cells in Metastatic Melanoma Patients by Vaccination with Mature, Cryopreserved, Peptide-loaded Monocyte-derived Dendritic Cells

2002 • 484 citations

Effective migration of antigen-pulsed dendritic cells to lymph nodes in melanoma patients is determined by their maturation state.

2003 • 479 citations

Rapid generation of broad T-cell immunity in humans after a single injection of mature dendritic cells

1999 • 466 citations

Cognate CD4+ T cell licensing of dendritic cells in CD8+ T cell immunity

2004 • 430 citations

Palliative therapy of disseminated malignant melanoma: a systematic review of 41 randomised clinical trials

2003 • 323 citations

The First 1000 Dendritic Cell Vaccinees

2003 • 277 citations

Adjuvant Immunotherapy of Resected, Intermediate-Thickness, Node-Negative Melanoma With an Allogeneic Tumor Vaccine: Impact of HLA Class I Antigen Expression on Outcome

2002 • 207 citations

[New guidelines to evaluate the response to treatment in solid tumors].

2000 • 151 citations

Phase 2 Trial of Vaccination With Tyrosinase Peptides and Granulocyte-Macrophage Colony-Stimulating Factor in Patients With Metastatic Melanoma

2000 • 131 citations

Large-scale generation of mature monocyte-derived dendritic cells for clinical application in cell factories™

2002 • 127 citations

Evaluation of in vivo labelled dendritic cell migration in cancer patients.

2004 • 117 citations

Dacarbazine and interferon α with or without interleukin 2 in metastatic melanoma: a randomized phase III multicentre trial of the Dermatologic Cooperative Oncology Group (DeCOG)

2001 • 89 citations

International Meeting on Cancer Vaccines

2004 • 52 citations

HLA allele frequency and clinical outcome in Italian patients with cutaneous melanoma

2004 • 18 citations